Latest news about Bharat Parenterals
Bharat Parenterals
1,441.20
+44.10(+3.16%)
Company Performance:
View Company Insights1D+3.16%
1M+10.27%
6M+10.27%
1Y+10.27%
5Y+10.27%
More news about Bharat Parenterals
30Jun 26
Promoter entity acquires shares in Bharat Parenterals
Promoter entity Desai Shares and Stock Private Limited acquired 1,356 equity shares in Bharat Parenterals Limited through open market transactions between June 15 and June 25, 2026. The purchase, valued at ₹18.06 lakh, increased the promoter's holding from 39.65% to 39.67%. The disclosure was made under Regulation 29 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
16Jun 26
Desai Shares raises stake to 39.65% in Bharat Parenterals
Desai Shares and Stock Private Limited, a promoter of Bharat Parenterals Limited, acquired 900 equity shares via open market transactions on BSE, increasing its holding to 39.65%. The shares were purchased between June 3 and June 12, 2026, for a total value of ₹12,62,164. The disclosure was submitted under SEBI (Prohibition of Insider Trading) Regulations.
20May 26
Bharat Parenterals FY26: PAT ₹1,601.89 L, Q4 Revenue ₹99.6 Cr
Bharat Parenterals reported a standalone net profit of ₹1,601.89 lakh for FY26, down from ₹2,645.36 lakh in the previous year, with consolidated revenue at ₹345.4 crore. The board recommended a final dividend of ₹1.00 per share. Innoxel Lifesciences turned EBITDA-positive in Q4, and Varenyam Healthcare returned to profitability. Management provided FY27 guidance, expecting commercial inflection with revenue growth of 10-15% for the standalone business and 35-45% for Innoxel.
29Apr 26
Bharat Parenterals Limited Publishes Share Transfer Notice Under SEBI Regulations
Bharat Parenterals Limited published newspaper advertisements on April 29, 2026, regarding proposed share transfers in physical form under SEBI Circular dated January 30, 2026. The WHO-GMP certified company disclosed this information to BSE under Regulation 30 of SEBI LODR Regulations, with advertisements appearing in Business Standard and Vadodara Samachar.
21Apr 26
Bharat Parenterals: U.S. FDA Issues 5 VAI Observations Following Surprise Inspection at InnoXel Lifesciences
U.S. FDA conducted surprise inspection at InnoXel Lifesciences facility, issuing 5 VAI observations. Bharat Parenterals awaits final Establishment Inspection Report. VAI classification indicates moderate regulatory concerns requiring correction but not immediate action.
10Apr 26
Bharat Parenterals Limited Responds to BSE Clarification on Stock Price Movement
Bharat Parenterals Limited responded to BSE's inquiry about stock price movements, confirming no undisclosed material information affects securities pricing. The WHO-GMP certified pharmaceutical company emphasized full regulatory compliance and attributed price changes to market forces. Company Secretary Sharmin Soni reaffirmed the company's commitment to transparency and corporate governance standards in the April 10, 2026 response.
08Apr 26
Bharat Parenterals Limited Issues Notice to Physical Shareholders for Share Transfer Re-lodgement
Bharat Parenterals Limited published newspaper advertisements on April 08, 2026, notifying physical shareholders about a special window for re-lodgement of share transfer deeds. Following SEBI Circular dated January 30, 2026, the company opened a one-year window from February 5, 2026 to February 4, 2027 for transfer deeds originally lodged before April 01, 2019 and rejected due to deficiencies. Eligible shareholders can submit requests to the company's R&TA, with processing to be done in dematerialized form only.
30Jan 26
Bharat Parenterals Q3FY26 Results: Revenue Declines 38.5% YoY to ₹41.41 Crore, Order Book at ₹303 Crore
Bharat Parenterals delivered mixed Q3FY26 results with standalone revenue declining 38.5% YoY to ₹41.41 crore due to timing delays in institutional orders. The company disclosed a strong order book of ₹303 crore for future execution and expects recovery in Q4FY26 with revenue guidance of ₹50-55 crore.
01Jan 26
Bharat Parenterals Limited Appoints Keval Sanjaykumar Shah as Vice President - Operations
Bharat Parenterals Limited has appointed Mr. Keval Sanjaykumar Shah as Vice President - Operations effective January 01, 2026, under SEBI Regulation 30 compliance. Mr. Shah brings over 10 years of experience in supply chain, project management, and business development, holding an MBA from IMT Ghaziabad. The company describes him as a results-driven professional whose expertise in operations management and strategic decision-making will support the organization's growth phase.
17Nov 25
Bharat Parenterals Q2 FY26 Revenue Dips 35% Amid Production Upgrades, Maintains Growth Outlook
Bharat Parenterals Limited experienced a 35.35% year-over-year revenue drop in Q2 FY26, with standalone revenue falling to ₹41.70 crore from ₹64.50 crore in Q2 FY25. The decline is attributed to planned production upgrades and deferred export dispatches. Despite this, the company maintains its FY26 guidance, projecting 12-14% revenue growth and 15-17% EBITDA margins. Its subsidiary, Innoxel, secured US FDA approval and signed 7 new partnerships worth $1.85 million, potentially boosting future performance.
28Jul 25
Bharat Parenterals Targets ₹350 Crore Revenue by FY26, Reports Strong Q1 Performance
Bharat Parenterals Limited (BPL) aims to achieve over ₹350 crore in consolidated revenue by FY26. Q1 saw strong performance with consolidated revenue up 25.4% to ₹116.00 crore. Growth strategies include expanding Innoxel's CDMO operations, scaling Varenyam Healthcare to ₹100 crore by FY28, and developing Varenyam Biolifesciences for regulated emerging markets. BPL projects 12-14% revenue growth and 15-17% EBITDA margin for standalone operations, with additional revenue targets for subsidiaries.
28Jul 25
Bharat Parenterals Announces Board Changes and Strong Q1 Performance
Bharat Parenterals Limited (BPL) reported Q1 consolidated revenue of ₹116.00 crores, up 25.40% year-on-year, with EBITDA at ₹13.78 crores. The company announced board changes including the appointment of Mr. Alkesh Shah as Non-Executive Director and re-appointment of Mr. Mukeshbhai Patel as Independent Director. BPL's subsidiaries show progress, with Innoxel Lifesciences developing over 20 differentiated molecules and Varenyam Healthcare present in 7,500+ hospitals. The company projects 12-14% standalone revenue growth for the current fiscal year.
28Jul 25
Bharat Parenterals Reports Q1FY26 Results, Announces Board Changes and AGM Date
Bharat Parenterals Limited (BPL) reported its Q1 FY26 results. Standalone revenue increased by 2.50% to ₹94.37 crore, while consolidated revenue grew 25.40% to ₹116.00 crore. The company narrowed its consolidated net loss to ₹0.87 crore. BPL projects standalone revenue growth of 12-14% for FY26 with an EBITDA margin of 15-17%. Board changes include Mr. Sanjay Shah's resignation and Mr. Alkesh Jayantilal Shah's appointment as Additional Non-Executive Non-Independent Director. The 32nd AGM is scheduled for September 26, 2025.
12May 25
Bharat Parenterals Q4 FY23: EBITDA Surges Despite Widening Net Loss
Bharat Parenterals Ltd. (BPL) released Q4 FY23 results showing strong operational growth but increased net loss. Revenue rose 47.49% YoY to ₹100.00 crore, EBITDA doubled to ₹22.00 crore with margin improving to 2.14%. However, net loss widened to ₹4.70 crore from ₹0.30 crore in Q4 FY22.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Dr Reddys Laboratories
Mankind Pharma
Laurus Labs
Aurobindo Pharma
1,910.00
(+0.40%)
8,496.00
(-1.17%)
4,886.50
(-0.20%)
1,437.90
(+0.40%)
1,103.80
(-1.45%)
2,188.00
(-0.63%)
1,190.00
(+1.30%)
2,374.50
(-0.40%)
1,801.00
(-0.06%)
1,608.00
(-0.82%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
